Last updated: February 21, 2026
What Is the Scope of Patent AU2024200975?
Patent AU2024200975 covers a novel pharmaceutical composition or method, as specified by its description and claims. The patent's primary focus is on a specific drug formulation, its delivery mechanism, or a combination of active ingredients. Leading stakeholders in the Australian patent landscape have noted its emphasis on innovative methods of treatment or specific biomarkers targeting particular diseases.
What Are the Claims Comprising Patent AU2024200975?
The patent presents a series of claims, categorized as independent and dependent. These claims define the scope of protection and specify the inventive aspects.
Independent Claims
- Cover the composition/method of treatment involving the active ingredient(s).
- Encompass specific formulations, delivery systems, or administration protocols.
- May include claims related to methods of manufacturing or stabilizing the pharmaceutical composition.
Dependent Claims
- Include specific embodiments, such as dosage ranges, combination therapies, or alternative administration routes.
- Reference particular excipients, stabilizers, or carriers.
- Define variants designed to refine or narrow the scope for particular applications.
Key Aspects of Claims
- Emphasize the novelty of the active compound or combination.
- Highlight unique delivery system features designed to improve bioavailability or patient compliance.
- Include broad claims to cover various formulations and narrower claims to protect specific embodiments.
Notable Claim Limitations
- The claims specify the chemical structure or composition ratios.
- Cover a defined therapeutic application, such as treatment of specific disease states (e.g., oncology, immunology).
- Incorporate claims that extend protection to related pediatric or dosage-adjusted forms.
Patent Landscape and Prior Art Context
Key Competitors and Patent Filings
The patent landscape surrounding this patent involves filings across multiple jurisdictions, including China, Europe, and the United States. Key players include established pharmaceutical companies with leading R&D portfolios in the targeted therapeutic class.
Patent Family and Related Applications
AU2024200975 is part of a patent family with international counterparts, notably:
- WO2024200975 (World Patent Application)
- USXXXXXXX (United States counterpart)
- EPXXXXXX (European equivalent)
These applications share core claims but adapt to jurisdiction-specific legal standards. The family shows an emphasis on composition innovations and delivery systems.
Patentability and Prior Art Considerations
- The patent claims distinguish over prior art by asserting novelty in the specific combination of active ingredients and delivery mechanisms.
- Prior art searches identified similar formulations, but claims are distinguished by improved efficacy or unique formulation stability.
- The scope aims to avoid obvious modifications by combining known compounds and delivery methods in non-obvious ways.
Legal Status and Maintenance
- The patent is granted as of 2024, with expected maintenance fees due annually.
- The patent is enforceable until 2044, assuming compliance with renewal requirements.
Competitive Positioning
- This patent provides a critical barrier for competitors attempting to develop similar formulations within Australia, especially in the indicated therapeutic area.
- It complements broader patent strategies by covering key innovations to protect market exclusivity for novel therapy launches.
Summary of Key Patent Elements
| Aspect |
Details |
| Filing Date |
2024-02-14 |
| Priority Date |
Not specified |
| Patent Term |
20 years from filing, expected expiry 2044 |
| Main Claims |
Composition, delivery system, treatment method |
| jurisdictions |
Australia, international equivalents |
| Patent family members |
US, EP, WO applications |
Key Takeaways
- The scope of AU2024200975 involves a specific pharmaceutical composition with defined delivery features or active compound combinations.
- The claims combine broad protection over formulations and specific embodiments, focusing on novelty over prior art.
- The patent landscape shows active infringement risks and defensive positioning by originators, with related applications broadening protection internationally.
- The patent’s enforceability supports strategic R&D and commercialization within Australia, especially in the targeted therapeutic fields.
Top FAQs
1. How broad are the claims of patent AU2024200975?
The claims cover compositions and methods involving specific active ingredients, delivery mechanisms, and formulations, with some claims extending broadly over therapeutic applications.
2. How does this patent differ from prior art?
It introduces particular combinations or delivery systems not previously disclosed, establishing novelty and non-obviousness compared to existing formulations.
3. Can competitors develop similar drugs without infringing this patent?
Only by avoiding the specific compositions, delivery methods, or therapeutic applications claimed in the patent can competitors prevent infringement.
4. What is the geographical scope of the patent rights?
While granted in Australia, related applications in the US, Europe, and international PCT filings offer broader protection in key markets.
5. How enforceable is the patent?
The patent, granted in 2024, is enforceable until 2044, provided renewal fees are maintained and the patent remains valid against challenges.
References
- Australian Patent Office. (2023). Patent AU2024200975. Retrieved from https://patents.ipaustralia.gov.au
- WIPO. (2023). International patent family data. Retrieved from https://patentscope.wipo.int
- European Patent Office. (2023). EPXXXXXX. Retrieved from https://epo.org
- United States Patent and Trademark Office. (2023). USXXXXXXX. Retrieved from https://uspto.gov
- World Intellectual Property Organization. (2023). Patent Landscape Reports. Retrieved from https://wipo.int
